Anuh Pharma Ltd (ANUHPHR) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Anuh Pharma Ltd on NSE and BSE, with an AI summary of each filing.
Request received for withdrawal of application for reclassification of shareholding from "Promoter & Promoter Group" to "Public Category".
Others (Uncategorized) · 30 Oct 2026, 11:01 pm
Anuh Pharma Receives Withdrawal of Promoter Reclassification Application from Nina Vijay Shah Anuh Pharma Ltd. announced on 30th Oct'26 that promoter group member Mrs. Nina Vijay Shah has voluntarily withdrawn her application for reclassification from the 'Promoter Group' to the 'Public' category under Regulation 31A of SEBI LODR Regulations. Following this withdrawal, which supersedes the earlier intimation dated 20th May'26, she will continue to remain classified as part of the company's Promoter Group.
Unaudited Financial Results for the Quarter and half year ended 30th September, 2026.
Financial Result · 30 Oct 2026, 10:48 pm
Anuh Pharma Reports Strong Q2 FY27 Profit Growth Driven by Margin Expansion Anuh Pharma reported Q2 FY27 revenue from operations of Rs 18,524.14 lakhs, remaining flat YoY (Rs 18,588.27 lakhs in Q2 FY26) and down 4.4% QoQ. Net profit rose 47.3% YoY to Rs 1,121.31 lakhs from Rs 761.25 lakhs, while dipping 1.9% QoQ. EBITDA jumped 36.5% YoY to Rs 1,755.13 lakhs, expanding margins by 255 bps YoY to 9.47%. H1 FY27 PAT grew 42.3% YoY to Rs 2,263.80 lakhs. Operating cash flow improved significantly to positive Rs 2,668.23 lakhs for H1 FY27.
Anuh Pharma Limited has informed the Exchange regarding 'Financial Results'.
Financial Result · 30 Oct 2026, 10:30 pm
Anuh Pharma Reports Strong Q2 FY27 Profit Growth Driven by Margin Expansion Anuh Pharma reported Q2 ended 30th Sep'26 revenue from operations of ₹18,524.14 lakhs, marginally lower YoY versus ₹18,588.27 lakhs and down 4.4% QoQ. Despite flat top-line growth, net profit surged 47.3% YoY to ₹1,121.31 lakhs (QoQ: ₹1,142.49 lakhs), driven by operating efficiencies. EBITDA rose 36.5% YoY to ₹1,755.13 lakhs with EBITDA margins expanding 255 bps YoY to 9.47%. Adjusted EBITDA reached ₹1,873.67 lakhs (10.11% margin). EPS stood at ₹1.12. For H1 ended 30th Sep'26, PAT climbed 42.3% YoY to ₹2,263.80 lakhs.
To consider and approve the Unaudited Financial results along with the Limited Review Report for the quarter and half year ended 30th September, 2026 and Request received for withdrawal ....
Outcome · 30 Oct 2026, 10:25 pm
Anuh Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 30 Oct 2026, 10:17 pm
Anuh Pharma Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakhs) ■ Revenue: 18,524 (-0.3% YoY | -4.4% QoQ) ■ EBITDA: 1,694 (+42.6% YoY | +4.0% QoQ) ■ EBITDA Margin (%): 9.1 (+276 bps YoY | +74 bps QoQ) ■ PAT: 1,121 (+47.3% YoY | -1.9% QoQ) ■ EPS (INR): 1.12 (+47.4% YoY | -1.8% QoQ)
ANUH PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-Oct-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business.
Intimation · 30 Oct 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026 and other business matters
Intimation · 30 Oct 2026, 5:30 am
Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2026 ,inter alia, to consider and approve Unaudited Financial Results for ....
Intimation · 30 Oct 2026, 5:30 am
Anuh Pharma Board Meeting Scheduled for 30th Oct'26 Anuh Pharma Ltd has scheduled a Board of Directors meeting on 30th Oct'26 to consider, approve, and take on record the company's unaudited financial results for the quarter and half-year ended 30th Sep'26. Additionally, pursuant to SEBI Insider Trading regulations, the company's trading window for designated persons and their immediate relatives has been closed from 1st Oct'26 and will remain closed until 1st Nov'26, which is 48 hours following the financial results declaration.
Intimation for receiving the possession of manufacturing facility
Others (Uncategorized) · 22 Oct 2026, 12:03 am
Anuh Pharma Takes Possession of Vanquest Pharma's Tarapur Manufacturing Facility Anuh Pharma Limited has received possession of the manufacturing facility of Vanquest Pharma Private Limited, located at MIDC, Tarapur, Boisar, Maharashtra. The acquisition was completed pursuant to an Asset Transfer Agreement executed on 16th Oct'26. The company confirmed there are no material changes to the transaction details disclosed in its prior intimation.
Disclosure of Events under Regulation 30 of SEBI LODR Regulation, 2015 for signing of Asset Transfer Agreement
Others (Uncategorized) · 17 Oct 2026, 12:24 am
Anuh Pharma Acquires Vanquest Pharma Manufacturing Facility for ₹72.90 Crore Anuh Pharma signed an Asset Transfer Agreement on 16th Oct'26 to acquire the API and intermediates manufacturing facility of Vanquest Pharma at Tarapur, Maharashtra, for a cash consideration of ₹72.90 crore (excluding taxes). The transaction encompasses land, buildings, plant, and machinery, and is expected to boost Anuh Pharma's overall production capacity by 525 MTPA. The non-related-party acquisition aims to strengthen the company’s manufacturing capabilities and market footprint in APIs and intermediates without any equity dilution or board appointments.
To Consider and Approve for investment in manufacturing assets for expansion and proposal for availing of loan for expansion
Others (Uncategorized) · 14 Oct 2026, 12:12 am
Anuh Pharma Approves Capacity Expansion and ₹75 Crore Loan Proposal Anuh Pharma Limited’s Board of Directors approved an investment in manufacturing assets to expand its production capacity on 13th Oct'26. To fund the purchase of these manufacturing assets, the Board also approved a proposal to avail a loan of up to ₹75 cr, subject to finalization of terms and receipt of applicable approvals. Detailed transaction terms and annexures will be disclosed subsequently in accordance with SEBI LODR regulations.
To Consider and Approve for investment in manufacturing assets for expansion and proposal for availing of loan for expansion
Others (Uncategorized) · 14 Oct 2026, 12:07 am
Anuh Pharma Approves Capacity Expansion and ₹75 Crore Loan Proposal Anuh Pharma's Board of Directors approved an investment in manufacturing assets to expand the company's production capacity on 13th Oct'26. To fund the purchase of these manufacturing assets, the board approved a proposal to avail a loan of up to ₹75 crs, subject to the finalization of terms and receipt of applicable approvals. Detailed disclosures will follow per regulatory requirements.
Disclosure under Regulation 30 of the SEBI LODR regarding receipt of Demand Order under Section 156 of the Income Tax Act, 1961.
Others (Uncategorized) · 18 Sept 2026, 9:27 pm
Anuh Pharma Receives Income Tax Demand Order Worth Rs 9.93 Lakh The Income Tax Department issued a demand order under Section 156 of the Income Tax Act, 1961, against Anuh Pharma Ltd. on 18th Sep'26. Pertaining to Assessment Year 2018-19, the demand amounts to Rs. 9,93,206 due to the disallowance of certain claimed deductions. Anuh Pharma stated that it will file an appeal before the CIT within prescribed timelines, maintaining strong legal grounds, with no anticipated impact on financial operations or ongoing business activities.
Investor Presentation for Q1 FY 2026-27
Investor Presentation · 19 Aug 2026, 10:16 pm
Anuh Pharma Q1 FY27: Margin Expansion Drives Strong Profit Growth Anuh Pharma reported strong Q1 FY27 results driven by margin expansion, with PAT at ₹11.42 Cr (+37.63% YoY) and EBITDA at ₹19.36 Cr (+41.56% YoY). Operating revenue grew modestly by 3.93% YoY to ₹193.81 Cr. The profit growth was attributed to a better product mix, cost controls, and a deliberate shift towards regulated markets. EBITDA margin improved significantly to 9.99% from 7.34% last year. ROCE for the quarter stood at 19.18%, up 326 bps vs FY26. The company anticipates 15-20% steady annual growth.
Disclosure under Regulation 30 of SEBI (LODR), 2015 regarding Change in Management.
Change in Management · 15 Aug 2026, 5:05 am
Anuh Pharma AGM Approves Director Reappointments and Remuneration Revisions Anuh Pharma’s 66th AGM approved key resolutions including director reappointments and remuneration revisions. Mr. Bipin Shah and Mr. Arun Todarwal were reappointed as Non-Executive Directors. Remuneration for Joint MDs, Mr. Ritesh Shah and Mr. Vivek Shah, was revised for FY27. The company also reappointed its cost auditor for FY27 and approved the adoption of a new Memorandum and Articles of Association. All resolutions were approved on 12th Aug’26, as per the filing on 14th Aug’26.
Disclosure of Announcement under Regulation 30 of SEBI (LODR), 2015
Others (Uncategorized) · 15 Aug 2026, 4:50 am
Anuh Pharma: Key Management Changes and Remuneration Revisions Anuh Pharma announced outcomes from its 66th AGM held on 12th Aug'26. Approvals include the reappointment of Non-Executive Directors Bipin Nemchand Shah and Arun Lalchand Todarwal. The company also revised the remuneration for Joint Managing Directors Mr. Ritesh B. Shah and Mr. Vivek Shah for FY 2026-27. Additionally, Mr. Ankit Kishor Chande was reappointed as Cost Auditor for the same fiscal year. The company's Memorandum and Articles of Association will also be updated, subject to shareholder approval.
Submission of Scrutinizer Report and Voting Results for the 66th Annual General Meeting of the Company
Annual General Meeting · 15 Aug 2026, 4:12 am
Outcome of the 66th Annual General Meeting of Anuh Pharma Limited held on Wednesday, 12th August, 2026
Annual General Meeting · 13 Aug 2026, 2:39 am
Adoption of Revised Policy of Related Party Transactions.
Others (Uncategorized) · 08 Aug 2026, 12:21 am
Anuh Pharma Q1FY27 Results Show Strong YoY Growth; Promoters Withdraw Reclassification Anuh Pharma reported strong Q1FY27 results for the quarter ending 30th Jun'26. Revenue from operations grew 3.9% YoY to ₹19,381 lakhs, while PAT rose 37.6% YoY to ₹1,142 lakhs. EBITDA increased 41.6% YoY to ₹1,936 lakhs, with the EBITDA margin expanding to 9.99% from 7.34% YoY. EPS for the quarter was ₹1.14. Concurrently, three promoter group shareholders, holding a combined 0.83% stake, withdrew their requests for reclassification from the promoter to public category, confirming their continued promoter status.
Request received for Withdrawal of application for reclassification of shareholding from "Promoter & Promoter Group'' to ''Public Category''.
Others (Uncategorized) · 08 Aug 2026, 12:13 am
Anuh Pharma: Promoter Group Withdraws Reclassification Request On 07th Aug'26, Anuh Pharma disclosed it received requests from promoter group members to withdraw their application for reclassification to the 'Public' category. The individuals—Vikram Kirtilal Shah, Kiran Piyush Shah, and Kinjal Siddharth Jhaveri—had previously sought reclassification on 20th May'26. Following this withdrawal, they will continue to be classified as part of the Promoter Group. This move reverses the earlier intention to reclassify their holdings, maintaining the promoter group's status quo.
Unaudited Financial Results for the Quarter ended 30th June, 2026.
Financial Result · 08 Aug 2026, 12:02 am
Anuh Pharma Q1FY27: Revenue Rises on Lower Margins Anuh Pharma reported Q1FY27 results with revenue from operations growing 3.9% YoY to Rs 19,381.04 lakhs. However, Profit After Tax (PAT) declined 2.2% YoY to Rs 1,142.49 lakhs. The decrease in profitability was driven by margin compression, with the EBITDA margin contracting to 9.99% from 7.34% last quarter but down from 11.66% in Q4FY26. Cost of materials consumed increased by 29.1% YoY, significantly impacting expenses. Basic Earnings Per Share (EPS) for the quarter stood at Rs 1.14, down from Rs 1.17 YoY.
To consider and approve the Unaudited Financial results along with the Limited Review Report for the quarter ended 30th June, 2026, Request received for withdrawal of application for reclassification ....
Outcome · 07 Aug 2026, 11:21 pm
Anuh Pharma Ltd - Financial Result for the Quarter ended 30th Jun'26 (Standalone, INR Lakh) ■ Revenue: 19,381 (+3.9% YoY | -4.1% QoQ) ■ EBITDA: 1,629 (+58.3% YoY | -18.1% QoQ) ■ EBITDA Margin (%): 8.4 (+289 bps YoY | -143 bps QoQ) ■ PAT: 1,142 (+37.6% YoY | -2.2% QoQ) ■ EPS (INR): 1.14 (+37.3% YoY | -2.6% QoQ)
Anuh Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/08/2026 ,inter alia, to consider and approve Unaudited Financial Results for ....
Intimation · 07 Aug 2026, 5:30 am
Anuh Pharma Board Meeting on 07th Aug'26 to Approve Q1FY27 Results Anuh Pharma Ltd. has scheduled a Board of Directors meeting on 07th Aug'26 to consider and approve the un-audited financial results for the quarter ended 30th Jun'26. In line with insider trading regulations, the trading window for designated persons has been closed from 01st Jul'26 and will reopen on 10th Aug'26, 48 hours after the results are declared. The meeting will also transact any other business with the permission of the chair.
This is to inform to the stock exchange regarding dispatch of physical communication to shareholders who have not registered their email address.
Others (Uncategorized) · 18 Jul 2026, 10:38 pm
Anuh Pharma Schedules 66th AGM and Dispatches FY26 Annual Report Anuh Pharma Ltd. has scheduled its 66th Annual General Meeting (AGM) for 12th Aug'26 at 4:00 p.m. IST via video conferencing. The company has dispatched its FY25-26 Annual Report and AGM notice electronically. On 18th Jul'26, Anuh Pharma also sent physical communications to shareholders without registered email addresses, providing a weblink to access the report. The company encourages all members to register their email and consider dematerializing physical shares to ensure seamless communication and compliance with SEBI guidelines.
Pursuant to the provisions of Regulation 34(1) of the SEBI (Listing Obligation and Disclosures Requirements) Regulations, 2015 please find enclosed herewith the copy of the Annual Report ....
Others (Uncategorized) · 18 Jul 2026, 10:03 pm